CAR mechanics: driving T cells into the MUC of cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 19487277.
- Also identified by DOI 10.1158/0008-5472.CAN-09-0564.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Several monoclonal antibodies bind in a highly selective manner to tumor-associated glycoforms of MUC1. We set out to exploit this by developing a MUC1-specific chimeric antigen receptor. Difficulties were encountered in this endeavor, owing to MUC1-imposed steric hindrance and antigenic heterogeneity. These issues were addressed by the iterative engineering of all components of the fusion receptor. Our experience underlines the need for careful individual optimization of immunotherapeutic reagents as dictated by the molecular vagaries of the target under study.
Medical subject headings
- Chemotaxis, Leukocyte
- Immunotherapy
- Mucin-1
- Neoplasms
- Receptors, Antigen, T-Cell
- Recombinant Fusion Proteins
- T-Lymphocytes